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Abstract 
 
Objective: Previous studies have found that oxytocin (OXT) can improve the recognition of 
emotional facial expressions; it has been proposed that this effect is mediated by an increase 
in attention to the eye-region of faces. Nevertheless, evidence in support of this claim is 
inconsistent, and few studies have directly tested the effect of oxytocin on emotion 
recognition via altered eye-gaze. Methods: In a double-blind, within-subjects, randomised 
control experiment, 40 healthy male participants received 24 IU intranasal OXT and placebo 
in two identical experimental sessions separated by a 2-week interval.  Visual attention to the 
eye-region was assessed on both occasions while participants completed a static facial 
emotion recognition task using medium intensity facial expressions.  Results: Although OXT 
had no effect on emotion recognition accuracy, recognition performance was improved 
because face processing was faster across emotions under the influence of OXT. This effect 
was marginally significant (p < 0.06). Consistent with a previous study using dynamic 
stimuli, OXT had no effect on eye-gaze patterns when viewing static emotional faces and this 
was not related to recognition accuracy or face processing time. Conclusions: These findings 
suggest that OXT-induced enhanced facial emotion recognition is not necessarily mediated 
by an increase in attention to the eye-region of faces, as previously assumed. We discuss a 
number of methodological issues which may explain discrepant findings and suggest the 
effect of OXT on visual attention may differ depending on task requirements. 
Keywords: Oxytocin, affect recognition, eye-gaze, placebo, emotion, faces. 
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Oxytocin reduces face processing time but leaves recognition accuracy and eye-gaze 
unaffected 
 
The ability to accurately recognize emotional facial expressions facilitates our 
understanding of the intentions, feelings, and reactions of others, which is necessary for 
adaptive social functioning in interpersonal situations (Carr & Lutjemeier, 2005). The 
neuropeptide oxytocin (OXT) has been found to play a central role in the regulation of social 
behaviour and social cognition (Heinrich, von Dawan & Domes, 2009), and has generally 
been associated with a range of prosocial behaviors, including increased trust (Kosfeld, 
Heinrichs, Zak, Fischbacher & Fehr, 2005), and generosity (Zak, Stanton & Ahmadi, 2007). 
Because the ability to decode another’s facial expressions is necessary for social interaction 
and has been linked to prosocial behaviors, it is perhaps not surprising that OXT has been 
shown to improve the recognition of emotional facial expressions (for review see 
Shahrestani, Kemp & Guastella, 2013). Nevertheless, there appear to be inconsistencies 
across studies. While some studies report that OXT selectively improves the recognition of 
certain emotions, for example happiness (Marsh, Yu, Pine & Blair, 2010) and fear (Fischer-
Shofty, Shamay-Tsoory, Harari & Levkovitz, 2010), others report that OXT results in a 
general improvement in facial emotion recognition across emotions (Shahrestani et al., 2013), 
or indeed that OXT does not enhance recognition accuracy but instead improves the threshold 
at which emotions are recognised (Lischke et al., 2012b). In addition, there are now several 
examples of OXT increasing antisocial behaviors, including increased envy or gloating 
following relative financial loss or gain (Shamay-Tsoory, Fischer, Dvash, Harari, Perach-
Bloom & Levkovitz, 2009), and increased interpersonal violence inclinations in those prone 
to physical aggression (DeWall et al., 2014; for review see Beery, 2015). As a result, it is 
important that studies not only examine the conditions under which OXT appears to result in 
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increased prosocial or antisocial behavior, but also explore the mechanisms underlying these 
effects. 
It has previously been suggested that because the eye-region contains the most 
relevant cues for accurate emotion detection, an increase in attention to the eye-region can 
improve emotion recognition (Schyns, Petro & Smith, 2009). Consequently, it has been 
proposed that one mechanism through which OXT may promote enhanced emotion 
recognition is through increasing attention to the eye-region of faces.  Consistent with this 
proposal, a study by Guastella, Mitchell and Dadds (2008) found that participants who 
received OXT spent more time fixating upon the eye-region of neutral faces during a free 
gaze task, and returned more frequently to this area, compared to participants receiving 
placebo. Although this study did not consider different emotions, Guastella et al. suggested 
that OXT has a direct influence on the ability to understand the emotions of others. It has also 
been shown that OXT enhances the ability to infer emotions from subtle cues around the eye-
region (Domes, Heinrichs, Michel, Berger & Herpertz, 2007a), alters eye-gaze towards the 
eye-region of faces in individuals with autism spectrum disorder, whilst performing a gender-
judgement free gaze task (Andari et al., 2010), and increases gaze towards the eye-region of 
emotional expressions during an emotion classification task (Gamer, Zurowski & Buchel, 
2010). Furthermore, one study reported that OXT differentially modulates visual attention 
toward social signals of positive approach and threat (Domes, Steiner, Porges & Heinrichs, 
2013), and other studies have reported that OXT has no effect on eye-gaze towards static 
faces (Domes et al., 2010) or static scenes (Lischke et al., 2012a). Although these studies 
differ in terms of the type of task performed by participants and did not explicitly assess the 
link between eye-gaze and emotion recognition, they provide inconsistent support for the 
commonly assumed notion that OXT may improve emotion recognition by increasing 
attention to socially relevant stimuli, in this case the eye-region. 
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To our knowledge, the only study to assess this link directly is the one reported by 
Lischke et al. (2012b), who found that whilst OXT improved the threshold for recognition 
(participants on OXT recognized emotions at lower intensities), eye-gaze and overall 
accuracy were unaffected. This study was conducted using dynamic faces, changing from low 
to high intensity. The authors suggested that the eye-region may be less salient in dynamic 
faces compared to static faces, and that attention may be captured more by the eyes in static 
faces because the eyes are assumed to be the most informative part of the face (Adolphs, 
Baron-Cohen & Tranel, 2002). Indeed, it has been shown that the relative importance of the 
eyes reduces when using dynamic faces (e.g., Vo, Smith, Mital & Henderson, 2012). A key 
next step would therefore be to determine whether OXT alters eye-gaze to static emotional 
faces.  
In response to recent reviews that have been critical of the quality and rigor of OXT 
research (Churchland & Winkielman, 2002; Leng & Ludwig, 2016; Walum, Waldman & 
Young, 2016), we aimed to replicate previous findings of the effects of OXT on facial 
emotion recognition using a larger sample. Furthermore, a between-subject design was used 
in the only study so far to examine OXT, eye-gaze and emotion recognition (Lischke et al., 
2012b). Given large variations in individual responsivity to OXT across participants 
(Daughters et al., 2015), we considered it important to explore the effects of OXT using a 
within-subjects design and to take measures of saliva OXT levels to ensure that the nasal 
sprays had the intended effect on OXT levels. 
To this end, we compared facial emotion recognition across the six basic emotions, 
using a double-blind, within-subjects, randomized control trial of intranasal OXT. An 
additional aim was to explore the mechanism by which OXT affects facial emotion 
recognition by measuring eye-gaze. In order to achieve these aims, participants completed a 
facial emotion recognition task using medium intensity, whole, static faces whilst their eye 
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movements were tracked with an eye-tracker. Saliva samples were taken and analyzed to 
ensure that OXT levels were elevated in the OXT condition. 
In line with evidence suggesting OXT enhances prosocial behavior, and consistent 
with evidence from Shahrestani et al. (2013), we hypothesized that OXT would generally 
enhance facial emotion recognition across emotions and in particular lead to improvements in 
the recognition of happiness and fear. We further expected OXT to increase attention to the 
eye-region of faces, and that this would be related to improvements in facial emotion 
recognition.  
Method 
Participants 
Forty healthy male students (Mage = 20.98; SD = 4.55) from Cardiff University 
participated in this experiment in return for course credit or £40. Participants took part in two 
3-hour study sessions, with a 2-week interval between each session (for practical reasons 
seven participants had to be tested at later dates; the longest interval between the two sessions 
was 35 days). The order in which they received OXT or placebo nasal spray was randomized 
and counterbalanced, with researchers and participants remaining blind to this order. The 
decision to examine OXT in male participants was taken for two reasons: (1) the effects of 
OXT have been shown to differ in males and females, meaning grouping across genders 
would not be appropriate (Domes et al., 2010; Kirsch et al., 2005); and (2) administering 
OXT to females entails additional ethical and logistical considerations (e.g., controlling for 
menstrual cycle phase and/or pregnancy).  
Ethical Statement 
The study was approved by both the School of Psychology Ethics Committee at 
Cardiff University, and by the Research and Development Office at Cardiff and Vale 
University Health Board. Participants were cleared to participate in the study by a medical 
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professional (co-author A.R.) and gave written informed consent at each testing session. They 
were fully debriefed after the second session. They completed medical pre-screening forms 
and signed statements of health before leaving each testing session. All participants had 
normal or corrected-to-normal vision, and none of them reported a history of neurological or 
mental health disorder, or severe allergic reactions. Participants were asked to refrain from 
alcohol in the 24 hours prior to each study session and from smoking cigarettes or drinking 
caffeine 2 hours prior to each study session. 
Measures and Materials 
Emotion recognition. Emotion recognition was tested using a shortened version of 
the Facial Emotion Recognition (FER) task (Bowen, Morgan, Moore & van Goozen, 2014).  
The shortened test consisted of 78 slides taken from the Ekman and Friesen (1975) facial 
affect battery, representing the six basic emotions (happiness, anger, fear, sadness, disgust 
and surprise) and neutral faces. Equal numbers of male and female targets appear in the photo 
stimuli; each emotion is expressed at two medium intensities (50% and 75%) in the slides. 
Only medium intensity facial expressions were examined in order to reduce the risk of ceiling 
and floor effects associated with high (100%) and low (25%) intensity facial expressions (see 
Bowen et al., 2014, for data on 25% and 100% intensities). The hair and background of the 
image was masked so that only the facial features remained (see Figure 1). 
The question “What emotion is this person showing?” accompanied the target image, 
along with numbered options from 1 to 7.  The options were (from 1 to 7) “happiness,” 
“sadness,” “fear,” “anger,” “disgust,” “surprise,” and “neutral.”  Percentage correct 
recognition scores for each emotion at each intensity level were calculated. Reliability for the 
overall accuracy score was satisfactory (Cronbach’s alpha = 0.68), as was test–retest 
reliability (r = 0.68, assessed by comparing participants’ first and second session scores, 
regardless of drug order). 
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INSERT FIGURE 1 HERE 
 
Eye-tracking. Participants were positioned approximately 60-65 cm from a laptop 
computer and a 9-point calibration was performed. The quality of calibration was checked; if 
there were no data for one or more points, or if calibration quality was poor, calibration at 
those points was repeated. This process was completed for a maximum of three calibration 
attempts, at which point it was unlikely that calibration would improve further. Seven 
participants were excluded due to poor calibration quality. Calibration was followed 
immediately by the facial stimuli. Eye movements were recorded with a portable Tobii X2-60 
compact eye-tracker sampling at 60Hz with a screen resolution of 1920 x 1080. This 
equipment is robust to changes in head position, negating the need for a chin rest. An I-VT 
fixation filter with a minimum fixation criterion of 60 milliseconds sampled the average raw 
data of both eyes to produce information on eye positions and duration. Eye-gaze validity 
was checked using a sample rate percentage that gives an estimate of the quality of the eye-
tracking in a recording by providing a percentage score of successfully-recorded data. Three 
participants whose validity fell below 70% (range = 14–44%), meaning eye-tracking data 
were not available for more than 30% of the recording, were excluded from the final analysis. 
For the remaining participants, validity ranged from 73–96% (M = 90%).  The 10 excluded 
participants did not differ from those whose eye-tracking data were retained with respect to 
performance on the FER task (overall accuracy: included = 75.2%, excluded = 74.4%, p > 
.05), age (included = 21, excluded = 23, p > .05), or drug order (six received OXT first, four 
received PL first). 
Saliva samples. Participants produced four saliva samples during each session: at 
baseline, and 30, 60, 90 minutes after OXT/placebo administration. These were analyzed to 
measure saliva OXT at each of these time points. Saliva analyses revealed the OXT nasal 
OXYTOCIN, FACIAL EMOTION RECOGNITION AND EYE-GAZE 9 
 
 
 
sprays were successful in increasing OXT levels: Mean saliva oxytocin concentration (in 
pg/ml) for all participants 30 min. after administration was 999.5 during OXT and 37.5 
during PL (see Daughters et al., 2015). When participants excluded from the eye-tracking 
analysis were removed mean saliva OXT concentration after 30 minutes was 1129.6 during 
OXT and 39.2 during PL. There were no significant differences in OXT concentrations 
between those included and excluded from the eye-tracking analysis (p>.05)  
 
Procedure  
Participants self-administered 24 IU (three 4IU puffs per nostril) of synthetic OXT or 
an independently manufactured placebo nasal spray (PL) that chemically matched the OXT 
spray for all compounds, except OXT. Both sprays were manufactured by St Mary’s 
Pharmaceutical Unit, Cardiff (http://www.wales.nhs.uk/sites3/home.cfm?orgid=828). A 
doctor was present during administration, and for the subsequent 15 minutes. After a 30-
minute wait period to allow the drug to take effect, participants completed the FER task. The 
FER, as described above, was presented immediately after calibration was completed. Each 
face was presented in a set of three slides. The first was a noise screen that was used to 
prevent any visual carryover effects from the previous slide; the second contained a fixation 
cross to control for participants’ starting eye position; the final slide contained the face 
stimulus. The noise and fixation cross screens were displayed for one second each. The face 
stimuli were presented for as long as it took participants to select the emotion they judged the 
face to be showing. This is important because it enabled us to examine improvements in 
facial emotion recognition both in terms of accuracy and in terms of time spent processing 
the emotional stimuli. Once an emotion had been selected, the next set of three slides was 
presented. During the second session, participants completed an identical version of the FER, 
but with the facial stimuli presented in a different order. The use of a randomized and 
OXYTOCIN, FACIAL EMOTION RECOGNITION AND EYE-GAZE 10 
 
 
 
counterbalanced drug order combined with a change in stimulus presentation order and a 
minimal delay of two weeks between sessions mitigated any concerns about potential training 
effects associated with using identical versions of the same task. After completing the tasks, 
participants were debriefed about the aims of the study and asked to indicate which spray 
they thought they had received during each session, and how confident they were of this. 
Participants could not accurately report, above chance levels, during which session they 
received OXT (23 guessed correctly) X2(1)=0.9, p = .341. Moreover, participants who 
identified the correct spray order indicated that they were less certain of that order than those 
who reported the incorrect order (Correct M = 3.8; Incorrect M = 5.7), t(38) = 2.35, p =.024.  
 
Data Analyses  
Tobii analysis software was used to analyze eye movements, which allowed areas of 
interest (AOI) to be created and a variety of summary reports generated. The eyes were 
grouped into one area. A second AOI was created around the mouth, and a third around the 
face as a whole to allow for analysis to be generated purely on the basis of when participants 
were looking at the face (see Figure 2 for example AOIs).  Eye-gaze was analyzed for the 
duration of time participants fixated each face. Percentage dwell-time (the sum of the 
duration of all fixations to an area of interest divided by the total duration of time spent 
looking at the face) for each AOI was calculated. The percentage of time spent looking at the 
eye (Cronbach’s alpha = 0.96, test–retest reliability, r = 0.79) and mouth regions (Cronbach’s 
alpha = 0.95, test–retest reliability, r = 0.75) was subtracted from that of the whole face to 
produce a percentage of time spent looking at the rest of the face (Cronbach’s alpha = 0.87, 
test–retest reliability, r = 0.72). The mean time spent looking at each face was also recorded 
                                                 
1 Identical analysis carried out removing the 10 participants who were excluded from the eye-
tracking analysis revealed similar results, X (1)= 1.2, p=.28. 
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as a measure of the time spent processing a face before a response was made (face processing 
time) (Cronbach’s alpha = 0.95, test–retest reliability, r = 0.80). 
 
INSERT FIGURE 2 HERE 
Analyses were carried out using SPSS 20 (SPSS Inc., Chicago, Illinois). The principal 
analyses reported below are analyses of variance. Where the assumption of sphericity was 
violated, Greenhouse-Geisser corrections were applied. Where follow-up tests were required, 
Bonferroni corrections were used. Effect sizes were calculated as partial eta squared (ηp2). 
 
Results 
Within-subjects ANOVAs were used, with Drug (OXT or PL), Emotion (happiness, 
sadness, fear, anger, disgust and surprise), and Intensity (50% or 75%) as factors. Separate 
analyses were carried out for the dependent variables of recognition accuracy and face 
processing time. 
Recognition Accuracy 
Recognition accuracy scores for six emotions during OXT or PL at 75% and 50% 
intensities are presented in Figure 3. There was a significant main effect of Emotion, F(3.86, 
150.6) = 48.35, p < .001, ηp2= .55; the recognition of happiness was the most accurate (M = 
94%, SD = 7), followed by the recognition of surprise (M = 84%, SD = 8), sadness (M = 75%, 
SD = 15), anger (M = 70%, SD = 14) and disgust (M = 64%, SD = 6); recognition of fear (M 
= 61%, SD = 15) was the least accurate. A significant Emotion x Intensity interaction, F(3.9, 
150.78) = 6.16, p < .001, ηp2 = .14, revealed that recognition accuracy was significantly 
greater for happiness, fear, sadness, disgust and angry faces when the intensity was higher 
(75%) (all ps < .001), but there was no significant difference as a function of intensity for 
surprise faces (p = .058). There was no significant effect of Drug, F(1, 39) = 0.11, p = .74, 
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ηp2= .00, and no interaction between Drug and Emotion, F(3.99, 155.73) = 0.93, p = .45, ηp2 = 
.02, Drug and Intensity F(1, 39) = 1.31, p = .26, ηp2 = .03, or Drug, Emotion and Intensity, 
F(3.88, 151.47) = 0.66, p = .62, ηp2 = .02.  
INSERT FIGURE 3 HERE 
Face Processing Time 
The effect of OXT administration on the time spent processing the face is shown in 
Figure 4. There was a main effect of Emotion, F(5, 145) = 7.58, p < .001, ηp2= .21, reflecting 
the fact that happiness recognition was fastest (M = 1.64, SD = 0.9), followed by disgust (M = 
1.85, SD = 0.6), surprise (M = 1.88, SD = 0.8) and sadness (M = 2.01, SD = 1.0). The longest 
face processing time was for the recognition of fearful (M = 2.12, SD = 1.0) and angry faces 
(M = 2.12, SD = 0.9). A main effect of Intensity, F(1,29) =20.04, p < .001, ηp2= .41, revealed 
that lower intensity faces required more face processing time (M = 2.05, SD = 0.9), compared 
to higher intensity faces (M = 1.82, SD = 1.0). There was a marginally significant main effect 
of Drug, F(1, 29) = 3.70, p = .06, ηp2 = .11, but no interaction between Drug and Emotion, 
F(2.37, 68.72) = 0.56, p = .60, ηp2 = .02, Drug and Intensity, F(1, 29) =0.66, p = .42, ηp2= .02 
or Drug, Emotion and Intensity, F(3.68,106.69) = 0.73, p = .56, ηp2 = .03. 
INSERT FIGURE 4 HERE 
 
Eye-gaze 
To examine the effect of OXT administration on visual attention, a 4-way (Drug x 
Emotion x Intensity x AOI) repeated measures ANOVA was conducted. This analysis 
revealed that the overall dwell-time to the eye or mouth regions was unaffected by OXT 
administration (main effect Drug: F(1, 29) = 2.84, p = .10, ηp2 = .09; by the interaction 
between Drug and Emotion: F(2.93, 85.19) = 2.18, p = .10, ηp2 = .07; the interaction between 
Drug and AOI: F(1, 29) = 0.51, p = .48, ηp2 = .02; the interaction between Drug and Intensity 
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F(1, 29) = 0.98, p = .33, ηp2 =.03 ; the three-way interaction between Drug, Emotion, and 
AOI: F(2.62, 76.0) = 0.85, p = .46, ηp2 = .03; the three-way interaction between Drug, 
Intensity, and AOI: F(1, 29) = 0.26, p = .61, ηp2 = .01; and the four-way interaction between 
Drug, Emotion, Intensity, and AOI: F(3.32, 96.20) =0.30, p = .85, ηp2= .01). A significant 
Emotion x AOI interaction, F(3.37, 97.68) = 18.86, p < .001, ηp2= .39,  reflected the fact that 
participants spent proportionally more time fixating on the eye-regions of sad (M = 66%, SD 
= 20) and fearful faces (M= 66%, SD= 19), followed by those of surprised (M = 62%, SD = 
16), disgusted (M = 61%, SD = 20), and angry faces (M = 59%, SD = 20). Percentage of time 
fixating upon the eye-region was lowest for happy faces (M = 55%, SD = 19). By contrast, 
participants spent a greater proportion of time fixating upon the mouth region of happy faces 
(M = 12%, SD = 13), followed by angry (M = 11%, SD = 10), fearful (M = 7%, SD = 8), 
surprised (M = 6%, SD = 6), and disgusted faces (M = 6%, SD = 6). Percentage of time spent 
fixating on the mouth region was lowest for sad faces (M = 5%, SD = 6). The main effect of 
AOI, F(1, 29) = 165.2, p < .001, ηp2 = .85, revealed participants spent significantly more time 
looking at the eye-region (M = 61.64%, SD = 18), compared to the mouth region (M = 7.85%, 
SD = 7). There was no main effect of intensity, F(1, 29) = .001, p =.973, ηp2 = .00, but the 
interaction between Intensity and AOI was significant, F(1, 29) = 8.85, p = .006, ηp2 = .23. 
Follow-up analyses revealed that participants spent proportionally more time looking at the 
mouth-region of 75% intensity faces than at the mouth-region of 50% intensity faces (M = 
7.1% vs. M = 8.6%, p = .001), but there was no difference in dwell time to the eye-region 
across intensities (p = .07). Because the Intensity variable had little effect on the overall 
patterns, the data have been collapsed across intensities to aid in the visual comparison of 
eye-gaze data shown in Figure 5. 
INSERT FIGURE 5 HERE 
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Association between Gaze to the Eye-Region, Emotion Recognition, Response Time and 
saliva OXT levels 
We computed separate Pearson’s correlation analyses between mean dwell-time to the eye 
region, emotion recognition accuracy and face processing time for the OXT and PL 
conditions. We found no evidence of an association between emotion recognition 
performance and dwell-time to the eye-region (OXT: r =.23, PL r = -.14), face processing 
speed (OXT: r =.14 =, PL: r = -.09) or gaze towards the eyes (OXT: r =.25, PL r = -.06), in 
either the OXT or PL condition (all ps > .05). Finally, within those who received PL first 
(n=22) overall recognition accuracy scores between the first and second (=OXT) session 
were highly correlated (r = .716, p<0.001). The correlations between individual saliva OXT 
concentrations and FER accuracy, dwell time and processing time were all non-significant 
(ps > .05). 
 
Table 1:  Inter-correlations between saliva OXT concentrations 30 min. after administration 
and key performance variables. Pearson’s R. 
 FER Dwell time to Face Processing 
time  Eye Mouth 
Saliva OXT -.03 -.05 .09 .09 
FER = Facial Emotion Recognition, OXT = Oxytocin, *p<.05, 
 
 
INSERT FIGURE 6 
 
Discussion 
We examined whether OXT affects facial emotion recognition and, if so, whether 
improvements were related to altered eye-gaze to socially relevant stimuli in static images. 
Using medium intensity emotional faces, we found that OXT did not improve facial emotion 
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recognition accuracy across emotions. This is inconsistent with our hypothesis that OXT 
would enhance emotion recognition across emotions, particularly for happiness and fear, and 
is also inconsistent with previous research (e.g., Shahrestani et al., 2013).  
Despite inconsistency in previous studies as to whether OXT selectively enhances 
recognition accuracy for certain emotions (i.e., fear or happiness) or whether it improves 
recognition in general, studies have typically found that OXT does result in some 
improvement in recognition accuracy. Indeed, in their recent meta-analysis Shahrestani et al. 
(2013) concluded that OXT enhances the recognition accuracy of basic emotions, with 
specific effects for the recognition of happiness and fear. The authors went on to discuss the 
effect of OXT in specific situations, and this may help explain the discrepant findings from 
the current study. For example, additional findings from the meta-analysis suggest that 
different stimulus exposure times could account for discrepancies. Under implicit recognition 
conditions (<300ms), OXT enhances recognition of happy and angry expressions. Given 
these expressions are generally recognized faster and more efficiently (Leppänen & Hietanen, 
2004; Fox et al., 2000), it is reasonable to conclude that OXT has effects at shorter stimulus 
durations but not with longer exposure times, where ceiling effects may occur. Because our 
study had no limit on exposure time, this may explain why we did not find improvements in 
the accurate identification of happy faces, but instead found some evidence (albeit marginally 
significant) that participants receiving OXT required less time to process the face.  By 
contrast, Shahrestani et al. (2013) found that for fearful expressions that tend to require more 
time to recognize and are generally harder to detect, OXT administration appears to have 
greater enhancing effects under longer durations of exposure (>300ms). This is not borne out 
by our findings, particularly regarding fear, where we found no improvements in facial 
emotion recognition accuracy independent of the specific emotion. It should be noted that in 
our study the average exposure time across emotions was 1930ms, with 2118ms for fear, 
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which is considerably longer than the 300ms that Shahrestani et al. (2013) refer to as a long 
exposure time. This may help to explain why, instead of OXT improving the accuracy of 
facial emotion recognition, it resulted in participants requiring less time to process the facial 
stimuli. Importantly, there was no relationship between face processing time and recognition, 
which suggests that OXT reduced the time required to process the face before an emotion 
was recognized without compromising accuracy.  
This finding is similar to that of Lischke et al. (2012b), who demonstrated that OXT 
reduced the threshold at which participants recognized an emotion, rather than enhancing the 
accuracy per se.  Conversely, Fischer-Shofty et al. (2010) found no effect of OXT on 
processing speed, but instead a selective effect of OXT on the enhancement of fear 
recognition. Given that both the current study and Lischke et al. used whole face stimuli, 
which have been shown to result in greater recognition accuracy compared to the eyes-only 
stimuli (Valla, Maendel, Ganzel, Barsky & Belmonte, 2013) employed by Fischer-Shofty et 
al., it is possible that OXT enhances recognition when task difficulty is high, but enhances 
efficiency when difficulty is low. Domes et al. (2007a) previously demonstrated that OXT 
improved facial emotion recognition performance for difficult test items, but not for easy 
ones; how this relates to efficiency is unknown. Future studies should address how accuracy 
and processing speed interact across tasks of varying difficulty.    
It is commonly suggested that improvements in facial emotion recognition associated 
with OXT are related to increased attention to the eye-regions of faces. However, evidence to 
support an effect of OXT on eye-gaze is mixed (e.g., Andari et al., 2010; Domes et al., 2010, 
2013; Gamer et al., 2010; Guastella et al., 2008; Lischke et al., 2012a). Moreover, in the only 
study to date to address the link between eye-gaze and improved facial emotion recognition 
explicitly (Lischke et al., 2012b), there was no effect of OXT on eye-gaze. The authors 
suggested this may have been due to the eye-region being less salient in the dynamic stimuli 
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used in their study.  Nevertheless, we observed similar results using static images. 
Specifically, we found that OXT did not result in increased fixations on the eye-region of 
faces across emotions. This is in contrast to previous studies which suggest OXT is 
associated with greater dwell-time to the eyes (Guastella et al., 2008; Andari et al., 2010). As 
previously mentioned, Lischke et al. suggested it is possible that their discrepant findings 
were due to the use of dynamic stimuli, because Guastella et al. (2008) and Andari et al. 
(2010) employed static faces. Our findings suggest that this is not the case. Interestingly, 
another difference between studies is that Guastella et al. and Andari et al. both examined 
eye-gaze in response to neutral faces, which required participants to passively view the faces 
or make gender or gaze direction judgments about them, whereas both Lischke et al. and the 
current study examined eye-gaze whilst participants were making emotional judgments. It is 
therefore possible that the effects of OXT are dependent on task requirements. Because the 
eye-region affords important information during emotional judgments, healthy participants 
are likely to have a preference for this area, whereas OXT may have more of an influence on 
where people look during passive viewing, or for tasks where the eye-region is less 
informative or less salient (e.g., gender judgments). As a caveat, it should also be noted that 
Gamer et al. (2010) found evidence that OXT altered eye-gaze during an emotional judgment 
task, but this was specifically in relation to OXT increasing the number of times participants 
shifted their gaze toward the eye-region, rather than percentage dwell-time to the region. 
Given that Gamer et al. presented stimuli for 150ms, these findings suggest that OXT is 
involved in the initial allocation of attentional resources, with the effect of OXT on eye-gaze 
becoming less relevant as stimulus exposure time increases. We recommend that future 
studies examine initial eye-gaze to stimuli presented for shorter durations, in order to 
examine whether percentage dwell-time to the eyes differs at lower exposure times. 
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What is evident from the studies that have examined eye-gaze changes following OXT 
administration, across a range of visual stimuli and tasks, is that the effects of OXT on eye-
gaze are inconclusive (e.g., Andari et al., 2010; Domes et al. 2010, 2013; Gamer et al., 2010; 
Guastella et al., 2008; Lischke et al., 2012a). Perhaps more importantly, the present results 
confirm findings from the only other study that directly examined the effect of OXT on the 
relationship between eye-gaze and facial emotion recognition. Taken together, these results 
indicate that there is no evidence that OXT improves facial emotion recognition by altering 
eye-gaze towards socially relevant information, in this case the eye-region. In addition to 
replicating the Lischke et al.’s findings using static stimuli, the current study also has the 
advantage of using a within-subject design.  
The current findings highlight the need to consider other mechanisms that may be 
responsible for the effects of OXT on behavior. One mechanism requiring further exploration 
is pupil dilation. A recent study by Prehn et al. (2013) suggests that, rather than OXT 
increasing visual attention to the eye-regions, enhanced recognition could be related to 
changes in pupil dilation, which can be used as a sensitive and reliable indicator of cognitive 
resource allocation and emotional arousal (Bradley, Miccoli, Escrig, & Lang, 2008). 
Specifically, better emotion recognition after OXT administration was accompanied by 
increased pupil dilation across emotions, which the authors attributed to an increased 
recruitment of attentional resources. This is consistent with OXT increasing attention towards 
socially relevant stimuli. However, the authors failed to address other possible explanations 
for the increase in pupil dilation. For instance, pupil dilation represents a measure not only of 
attentional resources but also of increased arousal, in particular sexual arousal (Rieger & 
Savin-Williams, 2012). It has also been previously demonstrated that OXT increases the 
perceived attractiveness of faces (Theodoridou, Rowe, Penton-Voak & Rogers, 2009). Taken 
together, these findings suggest it is possible that the increase in task-related pupil dilation 
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observed in Prehn et al.’s study was related to an increase in the perceived attractiveness of 
the stimuli, rather than attentional resources.  
Leknes et al. (2012) found similar results in a study examining evaluations of explicit 
and hidden happy and angry expressions. They demonstrated that administered OXT 
enhanced evaluations of facial expressions and led to greater pupil dilation during the 
identification of subtle and hidden emotional expressions. Although this study only examined 
angry and happy faces, it controlled for facial attractiveness, thereby eliminating this as a 
possible explanation for changes in pupil response. Moreover, Leknes et al. found that 
participants with lower emotional sensitivity and poorer baseline performance showed greater 
OXT-induced recognition improvement, in addition to a larger change in pupil dilation. In 
contrast, when emotional sensitivity was already high, OXT resulted in little or no 
improvement. Along similar lines, Bartz et al. (2010) found that OXT improved empathic 
accuracy only for participants who rated themselves as less socially proficient, as measured 
by the Autism Spectrum Quotient. The authors suggested that administered OXT increases 
the salience of social cues and benefits individuals who are generally less well tuned to social 
information, but does not benefit individuals who are more socially adept. Although our 
sample was too small to examine this issue properly, when we examined the effect of OXT 
separately in participants who scored in the bottom or top half on the FER test during the 
placebo condition, this analysis suggested that OXT significantly increased overall FER 
accuracy in low performers (Wilcoxon's signed rank test; Mdn [SD]: OXT = 73.6 [7.8], PL = 
70.8 [5.2]; Z = 2.0 p = .04), whereas it decreased performance in high performers (Mdn [SD]: 
OXT = 78.5 [8.7], PL = 81.2 [5.5]; Z = 2.1, p = .04). These preliminary findings add further 
weight to the suggestion that OXT may have greater effects in individuals with lower 
baseline emotion recognition accuracy.  
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Limitations  
It should be noted that we used only stimuli with emotional-social content, and face 
processing time was generally faster in all emotions in the OXT condition. Therefore, it is 
presently unclear whether OXT has an emotion-specific advantage or affects processing 
speed in general. To disentangle this, future studies should examine response times in relation 
to non-social and non-emotional tasks, whilst also considering traits such as confidence and 
risk taking. Given that we have demonstrated that facial emotion accuracy was not 
compromised as a result of faster response times, it is unlikely that an increase in impulsivity 
as a result of OXT can explain the findings.  However, a decrease in response time may be 
explained by OXT increasing participants’ confidence in their decisions or resulting in them 
taking more risks and thus responding faster. Both possibilities are worth exploring. 
Given that Shahrestani et al. (2013) suggested that discrepancies in the effect of OXT 
on facial emotion recognition could, in part, be related to different stimulus exposure times 
across studies, it could be considered a limitation of our study that we did not control for the 
amount of time participants viewed each facial stimulus. We took this decision because 
previous studies reported inconsistent findings on the effect of OXT on the accuracy and 
response time of emotional judgments. Not constraining exposure time provided us with 
additional insight into facial emotion recognition and enabled us to measure the time 
participants chose to attend to a face before making a response.  It is possible that our non-
significant findings for emotion detection accuracy were due to lower task difficulty 
compared to studies that restricted viewing time to a shorter duration. Nevertheless, 
happiness, sadness, fear, anger and disgust accuracy scores were significantly higher at 75% 
intensity than at 50% intensity. Given that the effect of OXT was consistent across intensities, 
this suggests that even when there was room for improvement (at 50% intensity), OXT had 
no effect on recognition accuracy.  Similarly, the mean recognition accuracy across emotions 
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in the placebo condition was 75% (SD = 8.3), with the variance in scores ranging from 55.5% 
to 90%, further demonstrating that ceiling performance had not been reached. The absence of 
a time constraint had the additional consequence that we were unable to analyze the number 
of fixations participants made to the eye and mouth regions – which is a common measure 
used in combination with dwell-time in eye-gaze studies – because this would have been 
confounded by the duration of time participants spent attending to the facial stimuli. Given 
that dwell-time is the most commonly reported eye-gaze measure within the OXT literature, 
this is not a major limitation of the current research, but corroboration with a measure of the 
number of fixations to the areas of interest would add to the strength of the findings. It is also 
worth addressing the number of participants whose data were excluded from this analysis 
because they failed the initial calibration test. Despite technical advice to the contrary, our 
experience with Tobii eye-tracking equipment suggests that the device is not suitable for use 
with participants who wear glasses; of the seven participants who failed the calibration 
process, six required glasses to complete the task. 
Participants in the OXT condition showed a trend towards requiring less time to 
process emotional faces. This effect was only marginally significant but of moderate effect 
size suggesting that it is quite likely that our study was underpowered to adequately detect 
effects. This has been a criticism of OXT studies in general, with Walum et al. (2016) 
suggesting that a sample size of more than 300 participants is needed to achieve sufficient 
power, compared to the average of 49 participants (between-subjects) used in previous 
studies. Whilst not achieving the sample size suggested by Walum et al., our study was an 
improvement on previous studies, particularly given that it benefitted from the use of a 
within-subject design and confirmed that OXT levels were indeed higher in the OXT 
condition. Nevertheless, it is clear that more needs to be done to ensure that OXT studies are 
sufficiently powered to detect significant effects. Given the challenges of running large-scale 
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OXT studies, this may involve replication of previous findings, cross-laboratory 
collaborations, or further exploration of the effects of OXT within populations who may be 
more susceptible to the effects of oxytocin, for example participants with autism.  
It should also be noted that we only examined the effect of OXT in males. This was 
for practical and ethical reasons. Evidence indicates that gender differences in emotion 
recognition exist and that OXT modulates the neural circuitry involved in face processing in 
men and women differentially. For example, while it has been demonstrated that OXT 
decreases amygdala activity in response to fear in men (Kirsch et al., 2005), it appears to 
increase amygdala activity to similar stimuli in women (Domes et al., 2010). Additionally, 
women are more accurate than men in recognizing medium intensity facial expressions 
(Hoffmann, Kessler, Eppel, Rukavina & Traue, 2010). Consequently, our results may not be 
generalizable to women.  
Finally, although we screened participants prior to testing for the presence of any 
mental health disorder we did not specifically screen for social cognitive disorders such as 
social anxiety, which may have allowed for a more detailed profile of the differential effect 
OXT has on different individuals to be examined.  
 
Conclusion and Clinical Implications 
In summary, our study using a high functioning, healthy, male sample provides 
preliminary evidence that OXT reduces the time required to process emotional expressions, 
but does not improve the accuracy of emotion recognition.  Importantly, our results counter 
the commonly proposed – but rarely tested – notion that the improvement in emotion 
recognition associated with OXT is the result of an increased attention to the eye-region; we 
replicated findings from previous studies using dynamic stimuli that OXT does not alter eye-
gaze when making emotional judgments. Taken together with previous findings, these results 
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suggest that OXT affects eye-gaze differentially, depending on task requirements. When 
participants are required to make emotional judgments about faces where the salience of the 
eye region is high, visual attention to the eye-region is unaffected by OXT; however, when 
participants perform tasks where the eye-region is less salient, OXT appears to increase 
attention to the eyes. These findings highlight the need for research to explore the differential 
effects OXT appears to have on different tasks. Given that the current study was conducted 
using normal, relatively socially adept individuals, it worth considering how these findings 
might be different for individuals, such as those with autism or antisocial behavior, who have 
problems recognizing emotions in others, and in voluntarily attended to the eye-region of 
others. 
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Figure captions 
Figure 1: Example stimuli selected from Bowen et al. (2014). 
Figure 2: Example face showing eye and mouth areas of interest (AOIs). 
Figure 3: Mean recognition accuracy scores as a function of Emotion, Drug and Intensity. 
Error bars indicate +2 SE. 
Figure 4: Mean face processing time as a function of Emotion, Drug and Intensity. Error bars 
indicate +2 SE. 
Figure 5: Mean percentage dwell-time as a function of Emotion, AOI and Drug. Error bars 
indicate +2 SE. 
Figure 6: Heat map reflecting total fixation duration in an example face (with red indicating 
higher concentration of fixations and green indicating lower concentration of fixations).  
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